NuCana plc - American Depositary Share (NCNA) News
Filter NCNA News Items
NCNA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest NCNA News From Around the Web
Below are the latest news stories about NUCANA PLC that investors may wish to consider to help them evaluate NCNA as an investment opportunity.
NuCana Reports Third Quarter 2023 Financial Results and Provides Business UpdateAnnounced Encouraging Updates from NUC-3373 and NUC-7738 Demonstrating Promising Efficacy and Safety Data Pipeline Continues to Advance with Data Updates Expected for all Programs in 2024 Well Capitalized with Anticipated Cash Runway into 2025 EDINBURGH, United Kingdom, Nov. 16, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the third quarter ended September 30, 2023 and provided an update on its broad clinical development program with its transformative ProTi |
NuCana Announces Listing Transfer to Nasdaq Capital MarketEDINBURGH, United Kingdom, Nov. 10, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced today that it has received approval from Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) to transfer the listing of its American Depositary Shares (“ADSs”) from the Nasdaq Global Select Market to the Nasdaq Capital Market. This transfer became effective at the opening of business on November 9, 2023. The Nasdaq Capital Market is a continuous trading |
NuCana to Present at the Jefferies London Healthcare ConferenceEDINBURGH, United Kingdom, Nov. 08, 2023 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies London Healthcare Conference. Event: Jefferies London Healthcare ConferenceDate: Tuesday, November 14, 2023Time: 8:00 AM GMTLocation: London, UK The presentation will be webcast live and available for replay under “Events & Presentations” in the Investo |
NuCana to Participate in the Truist Securities 2023 BioPharma SymposiumEDINBURGH, United Kingdom, Nov. 01, 2023 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host one-on-one meetings at the Truist Securities 2023 BioPharma Symposium. Event: Truist Securities 2023 BioPharma SymposiumDate: November 8-9, 2023Location: New York, NY About NuCanaNuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients wit |
NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023Data from the NuTide:701 Study Indicate NUC-7738 May Potentiate the Activity of Anti-PD-1 Agents in Patients who were Refractory to or Progressed on Prior Immunotherapy, including Anti-PD-1 Therapy Several Patients Achieved Reductions in Tumor Volume and Prolonged Time on Treatment BOSTON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced a presentation on the ongoing NuTide:701 study of NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer T |
NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023NUC-3373 Demonstrates Promising Anti-Tumor Activity and a Favorable Safety Profile as part of NUFIRI-bevacizumab and NUFOX-bevacizumab in Second-line Colorectal Cancer Patients Several Second-line Colorectal Cancer Patients in the NuTide:302 Study Achieved a Longer Progression-Free Survival as Compared to Their First-line Treatment with 5-FU-based Therapy NuTide:323 Randomized Study of NUFIRI-bevacizumab vs. FOLFIRI-bevacizumab in Second-Line Colorectal Cancer Patients Recruiting Well with No Ne |
Why Is NuCana (NCNA) Stock Down Today?NuCana stock is sliding lower as investors in NCNA prepare for presentations from the biopharmaceutical company later this week. |
RIVN Stock Alert: Rivian Scores a New ‘Buy’ RatingRivian Automotive stock is on the rise Tuesday after UBS analyst Joseph Spak upgraded shares of RIVN to a "buy" rating today. |
Why Is Akero Therapeutics (AKRO) Stock Down 58% Today?Akero Therapeutics (stock is falling hard on Tuesday after the company failed to impress AKRO investors with its clinical trial results. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time to dive into the biggest pre-market stock movers with all the most recent news moving shares on Tuesday morning! |